New vaccine trial offers hope for kids with Hard-to-Treat brain tumors
NCT ID NCT02358187
First seen Jan 10, 2026 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tests a vaccine made from proteins found on glioma cells, combined with an immune booster, in children whose low-grade gliomas have not responded to at least two prior treatments. The goal is to see if the vaccine can shrink the tumor or keep it from growing. About 25 children who carry a specific immune marker (HLA-A2) will receive up to 8 initial vaccines, with extra doses possible for up to two years if the tumor responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Pittsburgh of UPMC
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.